Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…
68,720€
3,34%
Echtzeit-Aktienkurs Halozyme Therapeutics
Bid:
Ask:
Nachrichten zur Halozyme Therapeutics Aktie
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Could Halozyme Therapeutics be the next big opportunity in biotech? Join our experts as they dissect the companys strengths and…
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?
Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.…
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
…
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…
Halozyme Therapeutics completes $1.5 billion convertible notes offering By Investing.com
Halozyme Therapeutics completes $1.5 billion convertible notes offering…
Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2025,…
Halozyme (HALO) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEMonday, Nov. 3, 2025 at 4:30 p.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — Helen TorleySenior…
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +5.52% and +5.10%, respectively, for the quarter ended September 2025. Do…
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Weeks Release
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…
Heres Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Halozyme Therapeutics, Inc. (HALO) Discusses To Acquire Elektrofi Conference Call (Transcript)
…
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day
Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.…
Halozyme Therapeutics Aktie: Mega-Katalysator durch FDA-Zulassung - Kursziel auf 85 Dollar erhöht
New York (www.aktiencheck.de) - Halozyme Therapeutics-Aktienanalyse von H.C. Wainwright & Co.:Die Analysten von H.C. Wainwright haben das Kursziel für die…
Bull of the Day: Halozyme Therapeutics (HALO)
The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth…
Halozyme Therapeutics stock hits all-time high at 77.6 USD By Investing.com
Halozyme Therapeutics stock hits all-time high at 77.6 USD…
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Halozyme Therapeutics - ENHANZE-Lizenzeinnahmen schieben Ergebnis deutlich an!
Geschäftstreiber: Der US-Biotechkonzern Halozyme Therapeutics (HALO) hat sich auf Produkte im Bereich proprietäre Enzymtechnologie spezialisiert. Die von Halozyme entwickelte ENHANZE-Technologie…
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter…
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do…
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Heres Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.…
Halozyme Therapeutics - ENHANZE-Lizenzeinnahmen sorgen für neue Rekorde bei Umsatz und Ergebnis!
Geschäftstreiber: Der US-Biotechkonzern Halozyme Therapeutics (HALO) hat sich auf Produkte im Bereich proprietäre Enzymtechnologie spezialisiert. Die von Halozyme entwickelte ENHANZE-Technologie…
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
3 Reasons Why Growth Investors Shouldnt Overlook Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.…
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Lets find out.…
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Halozyme mit starken Quartalszahlen und Erhöhung des Ausblicks für das Gesamtjahr - Aktie mit Up-gap!
Halozyme ist ein biopharmazeutisches Technologieunternehmen und verfügt über ein einzigartiges Geschäftsmodell, da es keine eigenen Arzneimittel entwickelt und mit seiner…
Halozyme nach geplatzter Evotec-Übernahme – Aktie startet jetzt durch
Im November vergangenen Jahres hat US-Biotech-Unternehmen Halozyme Therapeutics mit der geplanten Übernahme von Evotec für Aufsehen gesorgt. Das Vorhaben ist…
Halozyme nach geplatzter Evotec-Übernahme – Aktie startet jetzt durch
Im November vergangenen Jahres hat US-Biotech-Unternehmen Halozyme Therapeutics mit der geplanten Übernahme von Evotec für Aufsehen gesorgt. Das Vorhaben ist…
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter…
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.84% and 10.82%, respectively, for the quarter ended March 2025. Do…
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…
Halozyme Therapeutics: Schnell steigende Lizenzgebühren machen Halozyme zum Biotech-Top-Pick
Die Aktie von Halozyme war am 03.07.2024 eine der ersten Aktien, die ich im Rahmen dieser Rubrik vorgestellt hatte. Kurz…
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…
Halozyme Therapeutics: Steady Growth In A Challenged Market
…
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
Here is how Brookdale Senior Living (BKD) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this…
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.…
Heres Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
…
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the…
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 8.62% and 4.93%, respectively, for the quarter ended December 2024. Do…